Table. Prices and Characteristics of Cancer Medicines Recommended for Funding in Canada Between 2011 to 2020.
| Characteristic | Monthly price, median (range), US$a | P valueb |
|---|---|---|
| Drug | ||
| Total submissions | 6025 (782-26 388) | NA |
| Type of submission | ||
| New drug | 6148 (1723-32 480) | .96 |
| New indication | 5936 (782-34 305) | |
| Resubmission | 5683 (3188-9445) | |
| Type of recommendation | ||
| Conditional | 6184 (1723-34 305) | <.001 |
| Regular | 3289 (782-7298) | |
| Drug type | ||
| Immune checkpoint inhibitor | 8533 (5668-34 305) | <.001 |
| Monoclonal antibody | 6324 (3231-13 031) | |
| Small molecule inhibitor | 5481 (1723-17 992) | |
| Hormonal therapy | 2390 (2441-3497) | |
| Cytotoxic therapy | 4526 (3515-6820) | |
| Other | 3921 (782-17 500) | |
| Trial | ||
| Tumor type | ||
| Genitourinary | 3289 (2441-16 302) | <.001 |
| Melanoma | 8342 (782-34 305) | |
| Gastrointestinal | 4293 (2105-17 500) | |
| Breast | 4706 (2690-13 031) | |
| Lung | 6212 (1723-11 780) | |
| Gynecological | 6184 (4200-11 615) | |
| Other | 5647 (3231-8400) | |
| Treatment setting | ||
| Adjuvant | 7191 (5614-14 929) | .26 |
| Advanced or metastatic | 6025 (782-34 305) | |
| Single-arm | ||
| Yes | 6351 (782-24 360) | .24 |
| No | 5652 (1723-34 305) | |
| RCT evidence | ||
| Yes | 5812 (1723-34 305) | .75 |
| No | 6264 (782-10 933) | |
| Treatment linec | ||
| 1st | 6184 (1723-34 305) | .63 |
| 2nd and beyond | 6114 (782-32 480) | |
| Primary endpoint | ||
| OS | 6202 (2105-32 480) | .57 |
| PFS | 5376 (1723-34 305) | |
| RR | 6203 (2442-10 933) | |
| Other | 5521 (2442-14 929) | |
| Health-related quality of life | ||
| Assessed | 6184 (1723-34 305) | .17 |
| Not assessed | 4658 (782-11 615) | |
| ESMO-MCBS benefit | ||
| High | 6207 (1723-34 305) | <.001 |
| Low | 4437 (782-11 733) | |
| ESMO MCBS categoriesd | ||
| 1 | NA | .03 |
| 2 | 4898 (2690-11 733) | |
| 3 | 4164 (782-10 933) | |
| 4 | 6212 (1723-34 305) | |
| 5 | 6327 (6318-9035) | |
| A | 7191 (5614-14 929) | |
| B | NA | |
Abbreviations: ESMO-MCBS, European Society for Medical Oncology-Magnitude of Benefit Scale; NA, not available; OS, overall survival; PFS, progression-free survival; RR, response rate.
a
Prices reported in US$ after applying the exchange rate of September 3, 2022.
b
P values are unadjusted.
c
Treatment line applicable to medicines in advanced or metastatic setting.
d
There were no positive CADTH recommendations with an ESMO-MCBS score of 1 or B.